Targacept CEO J. Donald DeBethizy - An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
DeBethizy discusses the firm’s unique origins, its work with AstraZeneca and what’s ahead for the Raleigh, N.C.-based company.
You may also be interested in...
Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.
Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.
AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept
Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.